PPP1R12A and heart failure: The present study examined whether captopril treatment of heart failure maintains LZ+ MYPT1 expression by decreasing angiotensin II (Ang II) by testing the ability of angiotensin receptor blocker (ARB) therapy to maintain LZ+ MYPT1 expression and decrease the activation of either p42/44 or p38 MAPK.